[Phase II study of a new anthraquinone antineoplastic agent, mitoxantrone, in hematological malignancies].
At Saitama Cancer Center a phase II study of mitoxantrone was carried out in 18 patients with hematological malignancy. Mitoxantrone was given at either doses of 3, 5, or 6 mg/m2 daily X 5 in 8 patients with acute leukemia, while 10 patients with NHL were given intravenously at a dose of 10, 12, or 14 mg/m2 every 3 to 4 weeks. Although remission was not obtained in patients with acute leukemia, severe hypoplastic marrow was induced in 3 patients. Of 10 patients with NHL, one achieved CR, and 4 had a PR which lasted 31 weeks, 27 weeks, 19 weeks, 12 weeks +, and 9 weeks+. These patients had previous exposure to anthracyclines. Gastrointestinal toxicity and alopecia were less frequently seen and less severe with mitoxantrone.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000880:Anthraquinones / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone
D000880:Anthraquinones; D000970:Antineoplastic Agents; D008942:Mitoxantrone